StockData
Roivant Sciences Ltd. logo

Roivant Sciences Ltd.

ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.66−0.30 (-0.78%)

Close on Nov 20, 2026Market cap $27.92BP/E –Yield –

Roivant Sciences Arbutus Biopharma by Quarter

Arbutus Biopharma — Investment Fair Value (Level 1) ($M)

Periods

Roivant Sciences Arbutus Biopharma: $186M in Q2 FY2026, up 5.3% from a year earlier.

Latest, Q2 FY2026
186
Period ended Sep 30, 2026 (CQ3 2026)
Change on a year earlier
+5.3%
176 in Q2 FY2025
History
18 quarters
Since Q4 FY2021
Sources
17
Documents cited below

Where the Q2 FY2026 figure comes from

Source: Form 10-Q (filed 2026-11-09) ↗

Reported in Form 10-K / 10-Q (XBRL).

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedArbutus Biopharma — Investment Fair Value (Level 1) ($M)Year on yearSource
Q2 FY2026CQ3 2026Sep 30, 2026186+5.3%Form 10-Q (filed 2026-11-09) ↗
Q1 FY2026CQ2 2026Jun 30, 2026187+55.4%Form 10-Q (filed 2026-08-06) ↗
Q4 FY2025CQ1 2026Mar 31, 2026175+28.9%Form 10-Q (filed 2026-11-09) ↗
Q3 FY2025CQ4 2025Dec 31, 2025187+47.2%Form 10-Q (filed 2026-02-06) ↗
Q2 FY2025CQ3 2025Sep 30, 2025176+17.9%Form 10-Q (filed 2025-11-10) ↗
Q1 FY2025CQ2 2025Jun 30, 20251200.0%Form 10-Q (filed 2025-08-11) ↗
Q4 FY2024CQ1 2025Mar 31, 2025136+35.3%Form 10-K (filed 2026-05-20) ↗
Q3 FY2024CQ4 2024Dec 31, 2024127+30.8%Form 10-Q (filed 2025-02-10) ↗
Q2 FY2024CQ3 2024Sep 30, 2024150+89.6%Form 10-Q (filed 2024-11-12) ↗
Q1 FY2024CQ2 2024Jun 30, 2024120+34.4%Form 10-Q (filed 2024-08-09) ↗
Q4 FY2023CQ1 2024Mar 31, 2024100-14.9%Form 10-K (filed 2025-05-29) ↗
Q3 FY2023CQ4 2023Dec 31, 202397.1+7.3%Form 10-Q (filed 2024-02-13) ↗
Q2 FY2023CQ3 2023Sep 30, 202378.9+6.3%Form 10-Q (filed 2023-11-13) ↗
Q1 FY2023CQ2 2023Jun 30, 202389.3–Form 10-Q (filed 2023-08-14) ↗
Q4 FY2022CQ1 2023Mar 31, 2023118+1.6%Form 10-K (filed 2024-05-30) ↗
Q3 FY2022CQ4 2022Dec 31, 202290.5–Form 10-Q (filed 2023-02-13) ↗

Cite this data

StockData. (2026). Roivant Sciences Arbutus Biopharma ($M), quarterly Q4 FY2021–Q2 FY2026 [Data set]. Compiled from Roivant Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/roiv/kpis/fv-arbutus

See every metric in the Roivant Sciences KPI table. Data updated Nov 16, 2026.

See a number that looks wrong?